Florence Fevrier Wagner

This inventor holds 40 USPTO granted patents and 20 published patent applications, plus 3 CIPO patents and 10 EPO patents, primarily in HDAC Inhibitors. Top assignees: The Broad Institute, Inc., The General Hospital Corporation, Massachusetts Institute of Technology. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Florence Fevrier Wagner. Retrieved from https://idiyas.com/inventor/florence-fevrier-wagner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 20)

% Patents Active = 80.0

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 23)

Average Co-Inventor Count = 4.6

ph-index = 6

Forward Citations = 116(Granted Patents)

Location History:

Duluth, GA (US) (2010 - 2013)
Davis, CA (US) (2022)
Ashland, MA (US) (2012 - 2023)
Cambridge, MA (US) (2021 - 2024)

Company Filing History:

29 out of 486

The Broad Institute, Inc.

patents

13 out of 3,073

The General Hospital Corporation

patents

9 out of 8,586

Massachusetts Institute of Technology

patents

4. 7 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

5. 4 out of 1,428

The Brigham and Women's Hospital, Inc.

patents

6. 3 out of 5

Eikonizo Therapeutics, Inc.

patents

7. 3 out of 15

Instituto Carlos Slim De La Salud, A.c.

patents

8. 3 out of 16,025

University of California

patents

9. 2 out of 2

Altiris Therapeutics, Inc.

North Carolina State University

patents

12. 1 out of 1

Delix Therapeutics, Inc.

patent

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

HDAC6

Inhibitors

Kinase

Dopamine D2 Receptor

Toxic Proteinopathies

Tricyclic Compounds

Chemokine Receptor Modulators

Bicyclo Compounds

Fluorescent Substrates

Solid Forms

Memory Disorders

Cognition

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12655106 - HDAC6 inhibitors and uses thereof (2026-06-16),

2. 12590084 - Oxadiazole HDAC6 inhibitors and uses thereof (2026-03-31),

3. 12528767 - HDAC6 inhibitors and uses thereof (2026-01-20),

4. 12486289 - Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof (2025-12-02),

5. 12428373 - Dopamine D2 receptor ligands (2025-09-30),

6. 12419885 - Kinase inhibitors and methods of use thereof (2025-09-23),

7. 12325710 - Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders (2025-06-10),

8. 12295959 - Phenoxy and benzyloxy substituted psychoplastogens and uses thereof (2025-05-13),

9. 12048676 - Agents for reversing toxic proteinopathies (2024-07-30),

10. 12023308 - Agents for reversing toxic proteinopathies (2024-07-02),

11. 11840495 - Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds (2023-12-12),

12. 11572368 - Inhibitors of histone deacetylase (2023-02-07),

13. 11498896 - Dopamine D2 receptor ligands (2022-11-15),

14. 11414423 - Substituted 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles for treating brain disorders (2022-08-16),

15. 11377423 - Inhibitors of histone deacetylase (2022-07-05),

Title: The Innovative Journey of Florence Fevrier Wagner

Introduction:

Florence Fevrier Wagner, hailing from Ashland, MA (US), is a prolific inventor with an impressive portfolio of 28 patents. Her groundbreaking work focuses on developing agents for reversing toxic proteinopathies, addressing critical medical conditions such as MUC1-associated kidney disease, Retinitis Pigmentosa, and autosomal dominant tubulo-interstitial kidney disease.

Latest Patents:

Florence's latest patents center around compositions and methods for diagnosing, treating, and preventing proteinopathies caused by mutant protein accumulation in the secretory pathway. Specifically, she identifies TMED9-binding agents as effective in combating toxic proteinopathies and offers innovative techniques for discovering additional agents in this realm.

Career Highlights:

A significant part of Florence's career was spent at The Broad Institute, where she made notable contributions to the field of proteinopathy research. Her partnership with The General Hospital Corporation further exemplifies her dedication to advancing medical science through innovative patent applications.

Collaborations:

Throughout her career, Florence worked closely with esteemed colleagues such as Edward Holson and Michel Weiwer. These collaborations have not only enriched her work but also paved the way for groundbreaking advancements in the field of proteinopathy research.

Conclusion:

Florence Fevrier Wagner's remarkable journey as an inventor underscores her commitment to addressing complex medical challenges through innovative solutions. Her patents bear testimony to her relentless pursuit of excellence in the realm of proteinopathy research, leaving a lasting impact on the scientific community and beyond.

Profile summary based on public USPTO records.